OBJECTIVE: Limited data exist on the impact of regurgitation on health-related quality of life (HRQOL) in gastro-oesophageal reflux disease (GORD). We assessed the relationship between regurgitation frequency and HRQOL before and after acid suppression therapy in GORD. METHOD: We used data from two randomised trials of AZD0865 25-75 mg/day versus esomeprazole 20 or 40 mg/day in non-erosive reflux disease (NERD) (n=1415) or reflux oesophagitis (RO) (n=1460). The Reflux Disease Questionnaire was used to select patients with frequent and intense heartburn for inclusion and to assess treatment response. The Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire was used to assess HRQOL. RESULTS: At baseline, 93% of patients in both the NERD and RO groups experienced regurgitation. Mean QOLRAD scores were similar for NERD and RO at baseline and at week 4 and disclosed decremental HRQOL with increasing frequency of regurgitation; a clinically relevant difference of >0.5 in mean QOLRAD scores was seen with regurgitation ≥4 days/week versus <4 days/week. The prevalence of frequent, persistent regurgitation (≥4 days/week) at week 4 among heartburn responders (≤1 day/week of mild heartburn) was 28% in NERD and 23% in RO. QOLRAD scores were higher among heartburn responders. There was a similar pattern of impact related to regurgitation frequency in heartburn responders compared with the group as a whole. CONCLUSIONS: Frequent regurgitation was associated with a clinically relevant, incremental decline in HRQOL beyond that associated with heartburn before and after potent acid suppression in both NERD and RO. CLINICAL TRIAL NUMBERS: NCT00206284 and NCT00206245.
OBJECTIVE: Limited data exist on the impact of regurgitation on health-related quality of life (HRQOL) in gastro-oesophageal reflux disease (GORD). We assessed the relationship between regurgitation frequency and HRQOL before and after acid suppression therapy in GORD. METHOD: We used data from two randomised trials of AZD0865 25-75 mg/day versus esomeprazole 20 or 40 mg/day in non-erosive reflux disease (NERD) (n=1415) or reflux oesophagitis (RO) (n=1460). The Reflux Disease Questionnaire was used to select patients with frequent and intense heartburn for inclusion and to assess treatment response. The Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire was used to assess HRQOL. RESULTS: At baseline, 93% of patients in both the NERD and RO groups experienced regurgitation. Mean QOLRAD scores were similar for NERD and RO at baseline and at week 4 and disclosed decremental HRQOL with increasing frequency of regurgitation; a clinically relevant difference of >0.5 in mean QOLRAD scores was seen with regurgitation ≥4 days/week versus <4 days/week. The prevalence of frequent, persistent regurgitation (≥4 days/week) at week 4 among heartburn responders (≤1 day/week of mild heartburn) was 28% in NERD and 23% in RO. QOLRAD scores were higher among heartburn responders. There was a similar pattern of impact related to regurgitation frequency in heartburn responders compared with the group as a whole. CONCLUSIONS: Frequent regurgitation was associated with a clinically relevant, incremental decline in HRQOL beyond that associated with heartburn before and after potent acid suppression in both NERD and RO. CLINICAL TRIAL NUMBERS: NCT00206284 and NCT00206245.
Entities:
Keywords:
Anti-Reflux Therapy; Gastroesophageal Reflux Disease; Oesophageal Reflux; Oesophagitis; Quality of Life
Authors: Peter J Kahrilas; Andreas Jonsson; Hans Denison; Börje Wernersson; Nesta Hughes; Colin W Howden Journal: Am J Gastroenterol Date: 2012-07-10 Impact factor: 10.864
Authors: John Dent; Nimish Vakil; Roger Jones; Peter Bytzer; Uwe Schöning; Katarina Halling; Ola Junghard; Tore Lind Journal: Gut Date: 2010-06 Impact factor: 23.059
Authors: Leopold G J B Engels; Elly C Klinkenberg-Knol; Jonas Carlsson; Katarina Halling Journal: Health Qual Life Outcomes Date: 2010-08-17 Impact factor: 3.186
Authors: Philip B Miner; David A Johnson; Philip O Katz; Jing Li; Sergio C Gatoulis; Charles Pollack Journal: Adv Ther Date: 2018-09-25 Impact factor: 3.845